Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Witnessed versus unwitnessed random urine tests in the treatment of opioid dependence.

Mallya A, Purnell AL, Svrakic DM, Lovell AM, Freedland KE, Gott BM, Sayuk GS, Cicero TJ, Brawer PA, Trafton JA, Scherrer JF, Lustman PJ.

Am J Addict. 2013 Mar-Apr;22(2):175-7. doi: 10.1111/j.1521-0391.2013.00326.x.

2.

Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing.

Huestis MA, Cone EJ, Wong CJ, Umbricht A, Preston KL.

J Anal Toxicol. 2000 Oct;24(7):509-21.

PMID:
11043653
3.

Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.

Tofighi B, Grossman E, Goldfeld KS, Williams AR, Rotrosen J, Lee JD.

Subst Use Misuse. 2015;50(12):1571-8. doi: 10.3109/10826084.2015.1023455. Epub 2015 Nov 19.

PMID:
26623697
4.

Group medication management for buprenorphine/naloxone in opioid-dependent veterans.

Berger R, Pulido C, Lacro J, Groban S, Robinson S.

J Addict Med. 2014 Nov-Dec;8(6):415-20. doi: 10.1097/ADM.0000000000000071.

PMID:
25275875
5.

The Influence of Drug Testing and Benefit-Based Distribution of Opioid Substitution Therapy on Drug Abstinence.

Gabrovec B.

J Addict Nurs. 2015 Oct-Dec;26(4):208-12. doi: 10.1097/JAN.0000000000000098.

PMID:
26669228
6.

Methadone "callbacks" within a veterans affairs opioid treatment program: Detecting methadone misuse.

Cotton AJ, Shipley LJ, Glynn LH, Tracy J, Saxon AJ.

Am J Addict. 2017 Jan;26(1):50-52. doi: 10.1111/ajad.12479.

PMID:
28005315
7.

Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG.

JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302.

PMID:
25330017
8.

A comparison of random and post-accident urine opiate and opioid tests.

Price JW.

J Addict Dis. 2015;34(1):36-42. doi: 10.1080/10550887.2014.975614. Epub 2015 Mar 16.

PMID:
25774857
9.

Treatment changes following aberrant urine drug test results for patients prescribed chronic opioid therapy.

Morasco BJ, Krebs EE, Cavanagh R, Hyde S, Crain A, Dobscha SK.

J Opioid Manag. 2015 Jan-Feb;11(1):45-51. doi: 10.5055/jom.2015.0251.

PMID:
25750164
10.

The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.

Accurso AJ, Rastegar DA.

J Subst Abuse Treat. 2016 Feb;61:74-9. doi: 10.1016/j.jsat.2015.09.004. Epub 2015 Oct 1.

PMID:
26639639
11.

Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence.

Chawarski MC, Fiellin DA, O'Connor PG, Bernard M, Schottenfeld RS.

J Subst Abuse Treat. 2007 Dec;33(4):411-5. Epub 2007 May 23.

12.

Concordance between self-report and urine drug screen data in adolescent opioid dependent clinical trial participants.

Wilcox CE, Bogenschutz MP, Nakazawa M, Woody G.

Addict Behav. 2013 Oct;38(10):2568-74. doi: 10.1016/j.addbeh.2013.05.015. Epub 2013 Jun 13.

13.

Usefulness of the Brief Pain Inventory in Patients with Opioid Addiction Receiving Methadone Maintenance Treatment.

Dennis BB, Roshanov PS, Bawor M, Paul J, Varenbut M, Daiter J, Plater C, Pare G, Marsh DC, Worster A, Desai D, Thabane L, Samaan Z.

Pain Physician. 2016 Jan;19(1):E181-95.

14.

A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.

Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE.

J Addict Med. 2014 May-Jun;8(3):176-82. doi: 10.1097/ADM.0000000000000035.

PMID:
24695018
15.

Effectiveness of drug tests in outpatients starting opioid substitution therapy.

Dupouy J, Dassieu L, Bourrel R, Poutrain JC, Bismuth S, Oustric S, Lapeyre-Mestre M.

J Subst Abuse Treat. 2013 May-Jun;44(5):515-21. doi: 10.1016/j.jsat.2012.11.006. Epub 2013 Jan 20.

PMID:
23337248
16.

The cost of providing methadone maintenance treatment in Ontario, Canada.

Zaric GS, Brennan AW, Varenbut M, Daiter JM.

Am J Drug Alcohol Abuse. 2012 Nov;38(6):559-66. doi: 10.3109/00952990.2012.694518. Epub 2012 Jul 11.

17.

Opioid agonist treatment for pharmaceutical opioid dependent people.

Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N.

Cochrane Database Syst Rev. 2016 May 9;(5):CD011117. doi: 10.1002/14651858.CD011117.pub2. Review.

PMID:
27157143
18.

Superior methadone treatment outcome in Hmong compared with non-Hmong patients.

Bart G, Wang Q, Hodges JS, Nolan C, Carlson G.

J Subst Abuse Treat. 2012 Oct;43(3):269-75. doi: 10.1016/j.jsat.2011.12.006. Epub 2012 Jan 28.

19.

Slow-release oral morphine as maintenance therapy for opioid dependence.

Ferri M, Minozzi S, Bo A, Amato L.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD009879. doi: 10.1002/14651858.CD009879.pub2. Review.

PMID:
23740540
20.

Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.

Sankey C, Setnik B, Harsanyi Z, Michalko K, Yang Z, Geoffroy P.

J Opioid Manag. 2016 May-Jun;12(2):149-59. doi: 10.5055/jom.2016.0327.

PMID:
27194200

Supplemental Content

Support Center